Synthetic analogue of adrenocorticotropic hormone, ACTH(4-7)PGP delays neurological manifestations in diseases of mucopolysaccharidosis III spectrum by reducing neuroinflammation and rescuing neurotransmission, synaptogenesis, and axonal demyelination

This study demonstrates that intranasal administration of the synthetic peptide ACTH(4-7)PGP effectively delays neurological progression and extends lifespan in mouse models of Mucopolysaccharidosis III by reducing neuroinflammation, rescuing synaptic transmission and myelination, and improving cognitive and behavioral deficits without adverse effects.

The Gist

The Big Picture: A Broken Library and a Magic Key

Imagine the human brain as a massive, bustling library. In a healthy brain, books (nutrients and signals) are constantly being checked out, read, and returned to the shelves. The librarians (cells) keep everything organized, and the hallways (nerves) are wide and clear.

Sanfilippo Disease (MPS III) is like a library where the "return" system is broken. Because of a genetic glitch, the librarians can't break down a specific type of sticky, gooey paper (called Heparan Sulfate). This goo piles up everywhere.

• The Result: The shelves get clogged, the hallways get narrow, the lights flicker, and the librarians get angry and start shouting (inflammation). Eventually, the library stops working, leading to memory loss, behavioral issues, and early death in children.

Currently, there is no cure. Gene therapies (trying to fix the broken return system) have been tried, but they often arrive too late to fix the damage already done.

The New Discovery: This paper tests a new "magic key" called ACTH(4-7)PGP. It's a tiny, synthetic piece of a hormone that acts like a super-therapist for the brain. The researchers found that giving this key to mice with Sanfilippo disease didn't just clean up the goo; it actually repaired the library's wiring and calmed the angry librarians, delaying the disease and helping the mice live longer.

---

How the Magic Key Works (The 3-Step Rescue)

The researchers tested this drug on mice and human cells grown in a lab. Here is what happened, broken down into three simple steps:

1. Reconnecting the Wires (Synaptogenesis)

• The Problem: In the Sanfilippo brain, the connections between neurons (the "wires" that carry thoughts and memories) are frayed and broken. It's like a phone line with too much static; the message never gets through.
• The Fix: The drug acted like a construction crew. It helped grow new connections and repaired the old ones.
• The Evidence: When they looked at the brain cells under a microscope, the "wires" (synapses) looked healthy again. The mice could finally "talk" to each other properly.

2. Calming the Angry Mob (Reducing Inflammation)

• The Problem: Because the brain is clogged with goo, the immune cells (microglia) in the brain go into a panic mode. They start shouting and attacking everything, causing more damage. It's like a neighborhood where the police have gone crazy and are beating up innocent people.
• The Fix: The drug acted like a peacekeeper. It told the angry immune cells to calm down and stop shouting.
• The Evidence: The "angry" cells became quiet and helpful again. The brain's "noise" (inflammation) went down significantly.

3. Fixing the Insulation (Myelination)

• The Problem: Nerves are like electrical wires that need insulation (myelin) to work fast. In Sanfilippo, this insulation wears away, causing the signals to leak and slow down.
• The Fix: The drug helped re-insulate the wires.
• The Evidence: The brain scans showed that the "white matter" (the insulation) was preserved, allowing signals to travel fast again.

---

The "How" Behind the Magic

You might ask, "How does a tiny peptide know what to do?"

The researchers discovered the drug works by unlocking a specific door on the brain cells called the MC4 Receptor.

• The Analogy: Imagine the brain cell has a special keyhole (the receptor). When the drug turns this key, it triggers a chain reaction inside the cell.
• The Chain Reaction: It tells the cell to produce BDNF (Brain-Derived Neurotrophic Factor). Think of BDNF as fertilizer for the brain. It helps neurons grow, stay alive, and build new connections.
• The Bonus: At the same time, it flips a switch that stops the "angry shouting" (inflammation) by blocking a pathway called NF-kB.

The Results: A Second Chance

The study was impressive because it worked on two different types of Sanfilippo mice (Type A and Type C) and even on human cells grown in a dish.

• Behavior: The treated mice stopped being hyperactive and impulsive. They remembered where they had been before (memory) and weren't afraid of new things.
• Lifespan: The most dramatic result? The treated mice lived 8 weeks longer than the untreated ones. In mouse years, that's a significant extension of life, giving them more time to be healthy.
• Safety: The drug had no bad side effects. The mice didn't lose weight or get sick; they just got better.

The Bottom Line

This paper suggests that even if we can't fix the original genetic error (the broken return system), we can use a small, safe drug to fix the consequences of that error.

Think of it like this: If a house has a leaky roof (the genetic disease), you can't always fix the roof immediately. But if you use a special bucket and sealant (ACTH(4-7)PGP) to catch the water and patch the walls, the house stays livable for much longer.

The researchers are now ready to test this in humans. If it works in people the way it did in mice, it could be the first treatment that actually improves the quality of life and extends the lifespan of children with Sanfilippo disease, rather than just slowing the disease down.

Technical Summary

1. Problem Statement

Mucopolysaccharidosis III (MPS III or Sanfilippo disease) is a spectrum of four fatal lysosomal storage disorders (MPS IIIA-D) caused by genetic defects in enzymes responsible for degrading heparan sulfate (HS).

• Pathophysiology: HS accumulation in the central nervous system (CNS) triggers neuroinflammation (microglial/astrocyte activation), impairs vesicular trafficking, reduces dendritic spine density, and causes secondary accumulation of toxic proteins (e.g., GM2 ganglioside, SCMAS). This leads to progressive neurodegeneration, cognitive decline, behavioral abnormalities (hyperactivity, anxiety), and death in the second decade of life.
• Current Limitations: While gene therapies (AAV/LV) and enzyme replacement show promise in preclinical models, they have failed to reverse neurological symptoms in symptomatic patients. Crucially, reducing HS storage alone does not reverse established synaptic and circuit damage. There is an urgent need for therapeutic strategies that target downstream pathophysiological mechanisms, specifically synaptic dysfunction and neuroinflammation, rather than just the root enzymatic defect.

2. Methodology

The study employed a multi-faceted approach combining in vitro human and mouse models, in vivo mouse models, and advanced molecular imaging.

• Models:
  • Mouse Models: MPS IIIA (Sgsh^mps3a) and MPS IIIC (Hgsnat^P304L and Hgsnat-Geo knockout).
  • Human Models: iPSC-derived cortical neurons from patients with MPS IIIA, IIIB, and IIIC.
  • Primary Cultures: Mouse hippocampal neurons and microglia.
• Intervention: Intranasal administration of ACTH(4-7)PGP, a synthetic N-terminally acetylated heptapeptide analogue of adrenocorticotropic hormone (ACTH).
  • Dosage: 50 µg/kg body weight/day.
  • Route: Intranasal (non-invasive, bypasses blood-brain barrier).
  • Duration: Short-term (10–30 days) and long-term (starting at Postnatal day 30, P30, up to 8–11 months).
• Assessment Techniques:
  • Electrophysiology: Whole-cell patch-clamp recordings (mEPSC, mIPSC, AMPA/NMDA ratios) in acute brain slices.
  • Behavioral Testing: Open Field (OF), Elevated Plus Maze (EPM), Y-Maze (YM), Novel Object Recognition (NOR), Contextual Fear Conditioning (CFC), and Three-Chamber Sociability (TCS).
  • Molecular & Histological Analysis: Immunofluorescence (synaptic markers, neuroinflammation, myelin), Transmission Electron Microscopy (TEM), Diffusion Tensor Imaging (DTI), and quantitative RT-PCR.
  • Omics: Single-cell RNA sequencing (scRNA-seq) of hippocampal cells.
  • Mechanism Studies: Use of melanocortin receptor antagonists (SHU9119, HS024) and kinase inhibitors to map signaling pathways.

3. Key Contributions

1. Therapeutic Efficacy: Demonstrated that ACTH(4-7)PGP rescues synaptic transmission defects and behavioral abnormalities in two distinct MPS III mouse models (IIIA and IIIC) and human patient-derived neurons.
2. Mechanism of Action: Identified that the drug acts via Melanocortin Receptor 4 (MC4R) to activate the PI3K/AKT/CREB/BDNF signaling pathway, thereby promoting synaptogenesis and inhibiting neuroinflammation.
3. Pathology Reversal: Showed that the treatment reverses axonal demyelination, reduces secondary protein aggregates (GM2, SCMAS), and delays lethal urinary retention, without reducing the primary lysosomal storage of heparan sulfate.
4. Translational Potential: Validated intranasal delivery as an effective route for peptide delivery to the brain and provided preclinical justification for clinical trials.

4. Key Results

A. Restoration of Synaptic Function

• In Vitro: ACTH(4-7)PGP treatment (10 µM) restored levels of synaptic proteins (VGLUT1, PSD-95, SYN1) and BDNF in MPS III mouse neurons and human iPSC-derived neurons.
• In Vivo Electrophysiology: In MPS IIIA and IIIC mice, the drug rescued reduced miniature excitatory/inhibitory postsynaptic current (mEPSC/mIPSC) amplitudes and frequencies. It also normalized the AMPA/NMDA receptor ratio in CA1 hippocampal neurons, indicating restored excitatory transmission.

B. Behavioral Rescue

• Short-term: A 10-day treatment regimen rescued short-term memory deficits in the Novel Object Recognition (NOR) test and reduced hyperactivity/impulsivity in the Open Field and Elevated Plus Maze tests.
• Long-term: Daily treatment starting at P30 prevented the development of neurobehavioral deficits in MPS IIIA (social interaction, fear conditioning) and MPS IIIC mice. Treated MPS IIIC mice maintained normal behavior up to 8 months (terminal stage for untreated mice).

C. Structural and Pathological Improvements

• Synaptic Ultrastructure: TEM analysis revealed that ACTH(4-7)PGP restored the area of postsynaptic densities (PSD) and synaptic vesicle density in excitatory synapses to wild-type levels.
• Neuroinflammation: Treatment significantly reduced the density of activated microglia (CD68+) and astrocytes (GFAP+) and lowered pro-inflammatory cytokines (IL-1β, TNF-α, MIP-1α).
• Myelination: DTI and immunofluorescence showed restoration of white matter integrity (reduced radial diffusivity) and increased Myelin Basic Protein (MBP) levels, halting axonal demyelination.
• Secondary Storage: The drug reduced secondary accumulation of GM2 ganglioside, SCMAS, and Thioflavin-S-positive aggregates.
• Survival: In MPS IIIC mice, treatment extended the median lifespan by 8 weeks (from 41 to 49 weeks) and delayed the onset of lethal urinary retention.

D. Mechanism of Action (MC4R and BDNF Pathway)

• Receptor Specificity: The therapeutic effects (BDNF induction, synaptic rescue, anti-inflammatory action) were completely blocked by MC3/4R and selective MC4R antagonists, confirming MC4R as the primary target.
• Signaling Cascade: ACTH(4-7)PGP activates the PI3K/AKT and ERK pathways, leading to phosphorylation of CREB. This drives BDNF transcription.
• Anti-inflammatory Mechanism: In microglia, the drug increases IκBα levels and decreases NF-κB p65 phosphorylation, effectively inhibiting the NF-κB inflammatory pathway.
• scRNA-seq Findings: Sequencing confirmed that the drug reverses disease-induced gene expression changes, upregulating synaptic plasticity genes (e.g., Mef2c, Camk2d) and downregulating inflammatory markers in microglia and oligodendrocytes.

5. Significance

This study provides a compelling proof-of-concept that symptomatic treatment of MPS III is feasible even without correcting the primary enzymatic defect or clearing lysosomal storage.

• Clinical Relevance: Since most MPS III patients are diagnosed after symptoms appear, therapies that reverse synaptic and circuit damage are critical. ACTH(4-7)PGP (commercially known as Semax in some countries for stroke) has a known safety profile and can be administered intranasally, making it a strong candidate for immediate clinical translation.
• Paradigm Shift: The findings suggest that targeting downstream neuroinflammation and synaptic plasticity via the MC4R-BDNF axis is a viable strategy for treating not only MPS III but potentially other neurodegenerative disorders characterized by synaptic failure and neuroinflammation.
• Next Steps: The authors justify moving to clinical trials to test efficacy in human patients, particularly given the drug's ability to improve survival and quality of life in mouse models without adverse effects.